ESLA
Estrella Immunopharma Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$46.48M
P/E Ratio
—
EPS
$-0.34
Beta
0.85
52W High
$3.15
52W Low
$0.78
50-Day MA
$1.38
200-Day MA
$1.44
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Estrella Immunopharma Inc.
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company is headquartered in EmeryVille, California.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -268.50% |
| Return on Assets | -271.50% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-0.12 |
| Price-to-Book | 4.13 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -3.07 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $43.03M |
| Float | $14.11M |
| % Insiders | 60.61% |
| % Institutions | 12.15% |
Historical Volatility
HV 10-Day
77.26%
HV 20-Day
63.74%
HV 30-Day
62.37%
HV 60-Day
104.32%
HV Rank
17.5%
Volatility is currently expanding
Analyst Ratings
Consensus ($12.00 target)
1
BuyMore HEALTHCARE Stocks
Data last updated: 6/13/2026